Hydrocortisone tablets: alleged anti-competitive agreements and abusive conduct
The CMA is investigating alleged anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
|April to May 2017||Receipt of written and oral representations on the statement of objections|
|March 2017||Statement of objections issued|
|September 2016 to February 2017||Further information gathering and analysis of information requests|
|September 2016||Decision to continue with the investigation|
|August 2016 to September 2016||Investigation and analysis including further information requests and stakeholder meetings|
|April 2016 to July 2016||Initial investigation: information gathering, including issuance of formal or informal information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation|
|April 2016||Investigation opened|
Statement of objections
3 March 2017: The CMA issued a statement of objections alleging that Concordia and Actavis UK have breached UK and EU competition law by entering into anti-competitive agreements in relation to the supply of hydrocortisone tablets in the UK. In doing so, the CMA also alleges that Actavis UK abused its dominant position by inducing Concordia not to enter the market independently in the UK market.
- Press release: CMA alleges anti-competitive agreements for hydrocortisone tablets (2.3.17)
- The investigation is under Chapter I and Chapter II of the Competition Act 1998 (CA98) and Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU).
- No conclusion should be drawn that there has been an infringement of competition law at this stage and the recipients of the statement of objections will now have the opportunity to respond to the allegations.
- The CMA will consider any representations it receives before any decision is taken as to whether competition law has in fact been infringed.
- Changes to the timing of original entries in the case timetable will be made where the estimated timing changes.
Assistant Project Director
Emma Ngoga (0203 738 6752, email@example.com)
Project Director and Senior Responsible Officer
Andrew Groves (0203 738 6927, firstname.lastname@example.org)
Published: 12 April 2016
Updated: 3 March 2017
Opened: 12 April 2016
- Statement of objections issued
- Timetable updated.
- Timetable updated.
- First published.